NCT07096778 · CellCentric Ltd.
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
(DoMMino-1)
What this study is about
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving.
View original scientific description
The purpose of this study is to learn more about the anti-cancer activity of inobrodib, when given in combination with pomalidomide and dexamethasone, in patients with multiple myeloma that has come back following treatment and which no longer responds to available therapies. The study treatment will not be compared to any other treatment and patients will know what treatment they are receiving. This study will also further explore the side effects of inobrodib in combination with these other medicines.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Male or female ≥18 years of age
- Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy
- Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2
- Adequate hematological, renal and hepatic function
- Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners
Exclusion criteria
- Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest; any antibody based therapy within 30 days
- Prior treatment with p300/CBP bromodomain inhibitors
- Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)
- Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment
- Major surgery within 4 weeks of the first dose of study treatment
- Live vaccine within 4 weeks of study treatment
- Active or unresolved adverse events
- Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma
- Female patients who are pregnant or breast-feeding at any time during the study
- Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data
Where
- San Francisco, California
- Tampa, Florida
- Atlanta, Georgia
- Bethesda, Maryland
- St Louis, Missouri
- Omaha, Nebraska
- New Brunswick, New Jersey
- Charlotte, North Carolina
- Winston-Salem, North Carolina
- Cleveland, Ohio
- Philadelphia, Pennsylvania
- Seattle, Washington
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jun 2, 2026 · Source of record for eligibility and locations